In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
Saved in:
| Title: | In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium. |
|---|---|
| Authors: | Kurmasheva RT; Department of Molecular Medicine, Greehey Children's Cancer Research Institute, San Antonio, Texas., Erickson SW; RTI International, Research Triangle Park, North Carolina., Earley E; RTI International, Research Triangle Park, North Carolina., Smith MA; National Cancer Institute, Bethesda, Maryland., Houghton PJ; Department of Molecular Medicine, Greehey Children's Cancer Research Institute, San Antonio, Texas. |
| Source: | Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Feb; Vol. 68 (2), pp. e28772. Date of Electronic Publication: 2020 Oct 22. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
